260 related articles for article (PubMed ID: 20891010)
1. Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors.
Takeda S; Jiang R; Aramaki H; Imoto M; Toda A; Eyanagi R; Amamoto T; Yamamoto I; Watanabe K
J Pharm Sci; 2011 Mar; 100(3):1206-11. PubMed ID: 20891010
[TBL] [Abstract][Full Text] [Related]
2. One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
Rosati O; Messina F; Pelosi A; Curini M; Petrucci V; Gertsch J; Chicca A
Eur J Med Chem; 2014 Oct; 85():77-86. PubMed ID: 25072877
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
Johansson E; Halldin MM
J Anal Toxicol; 1989; 13(4):218-23. PubMed ID: 2550702
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandins and cannabis--XIII. Cannabinoid-induced elevation of lipoxygenase products in mouse peritoneal macrophages.
Burstein S; Hunter SA; Ozman K; Renzulli L
Biochem Pharmacol; 1984 Aug; 33(16):2653-6. PubMed ID: 6087836
[TBL] [Abstract][Full Text] [Related]
5. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2005 Mar; 174(6):3281-9. PubMed ID: 15749859
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandins and cannabis--XVI. Antagonism of delta 1-tetrahydrocannabinol action by its metabolites.
Burstein S; Hunter SA; Latham V; Renzulli L
Biochem Pharmacol; 1986 Aug; 35(15):2553-8. PubMed ID: 3017356
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ⁹-THC.
Coskun ZM; Bolkent S
Cell Biochem Funct; 2014 Oct; 32(7):612-9. PubMed ID: 25187240
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor.
Takeda S; Usami N; Yamamoto I; Watanabe K
Drug Metab Dispos; 2009 Aug; 37(8):1733-7. PubMed ID: 19406952
[TBL] [Abstract][Full Text] [Related]
9. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite.
Williams PL; Moffat AC
J Pharm Pharmacol; 1980 Jul; 32(7):445-8. PubMed ID: 6105177
[TBL] [Abstract][Full Text] [Related]
10. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.
Fraser AD; Worth D
Forensic Sci Int; 2004 Jul; 143(2-3):147-52. PubMed ID: 15240035
[TBL] [Abstract][Full Text] [Related]
11. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
Johansson EK; Hollister LE; Halldin MM
NIDA Res Monogr; 1989; 95():457-8. PubMed ID: 2561839
[TBL] [Abstract][Full Text] [Related]
12. The effect of Δ9-tetrahydrocannabinol on 5-HT3 receptors depends on the current density.
Yang KH; Isaev D; Morales M; Petroianu G; Galadari S; Oz M
Neuroscience; 2010 Nov; 171(1):40-9. PubMed ID: 20800662
[TBL] [Abstract][Full Text] [Related]
13. Combination of liquid chromatography with ultraviolet detection and gas chromatography with electron-capture detection for the determination of delta 9-tetrahydrocannabinol-11-oic acid in urine.
Karlsson L; Roos C
J Chromatogr; 1984 Mar; 306():183-9. PubMed ID: 6325483
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction and cross-tolerance between ethanol and Δ9-THC: possible modulation by mouse cerebellar adenosinergic A1/GABAergic-A receptors.
Dar MS
Behav Brain Res; 2014 Aug; 270():287-94. PubMed ID: 24875771
[TBL] [Abstract][Full Text] [Related]
15. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice.
Burstein S; Hunter SA; Latham V; Renzulli L
Experientia; 1987 Apr; 43(4):402-3. PubMed ID: 3032669
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
Takeda S; Yamamoto I; Watanabe K
Toxicology; 2009 May; 259(1-2):25-32. PubMed ID: 19428940
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.
Marcu JP; Christian RT; Lau D; Zielinski AJ; Horowitz MP; Lee J; Pakdel A; Allison J; Limbad C; Moore DH; Yount GL; Desprez PY; McAllister SD
Mol Cancer Ther; 2010 Jan; 9(1):180-9. PubMed ID: 20053780
[TBL] [Abstract][Full Text] [Related]
18. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production.
Shmist YA; Goncharov I; Eichler M; Shneyvays V; Isaac A; Vogel Z; Shainberg A
Mol Cell Biochem; 2006 Feb; 283(1-2):75-83. PubMed ID: 16444588
[TBL] [Abstract][Full Text] [Related]
19. Identification and determination of 11-oxo-delta8-tetrahydrocannabinol as an intermediate metabolite of delta8-tetrahydrocannabinol in the mouse brain and liver.
Watanabe K; Yamamoto I; Oguri K; Yoshimura H
J Pharmacobiodyn; 1980 Dec; 3(12):686-91. PubMed ID: 6268770
[TBL] [Abstract][Full Text] [Related]
20. Competitive inhibition of delta8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding.
Yamamoto I; Kimura T; Kamei A; Yoshida H; Watanabe K; Ho IK; Yoshimura H
Biol Pharm Bull; 1998 Apr; 21(4):408-10. PubMed ID: 9586583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
